If You’re A Risk-Taking Investor, Johnson & Johnson (NYSE: JNJ) Is Worth Taking A Chance On.

In the last trading session, 4.36 million shares of the Johnson & Johnson (NYSE:JNJ) were traded, and its beta was 0.53. Most recently the company’s share price was $157.78, and it changed around -$0.41 or -0.26% from the last close, which brings the market valuation of the company to $380.06B. JNJ currently trades at a discount to its 52-week high of $175.97, offering almost -11.53% off that amount. The share price’s 52-week low was $144.95, which indicates that the current value has risen by an impressive 8.13% since then. We note from Johnson & Johnson’s average daily trading volume that its 10-day average is 7.58 million shares, with the 3-month average coming to 7.12 million.

Johnson & Johnson stock received a consensus recommendation rating of Buy, based on a mean score of 2.27. If we narrow it down even further, the data shows that 2 out of 23 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 8 recommended JNJ as a Hold, whereas 8 deemed it a Buy, and 1 rated it as Underweight. Johnson & Johnson is expected to report earnings per share of $2.63 for the current quarter.

Johnson & Johnson (NYSE:JNJ) trade information

Instantly JNJ has showed a red trend with a performance of -0.26% at the end of last trading. The performance over the last five days has remained in the green territory. The company’s shares are currently up 0.66% year-to-date, but still up 1.64% over the last five days. On the other hand, Johnson & Johnson (NYSE:JNJ) is -2.23% down in the 30-day period. We can see from the shorts that 15.84 million shares have been sold at a short interest cover period of 2.19 day(s).

The consensus price target as assigned by Wall Street analysts is $180.33, which translates to bulls needing to increase their stock price by 12.5% from its current value. Analyst projections state that JNJ is forecast to be at a low of $163 and a high of $205.

Johnson & Johnson (JNJ) estimates and forecasts

Johnson & Johnson share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 0.57 percent over the past six months and at a 7.36% annual growth rate that is well above the industry average of 4.20%. Moreover, analysts have decided to roll up on their fiscal year 2024 revenue estimates. The rating firms predict that it will gain 9.10% in revenue this quarter, and will report an increase of 6.20% in the next quarter. The year-over-year growth rate is expected to be 12.10%, up from the previous year.

Consensus estimates provided by 14 financial analysts predict the company will bring in an average of $21.4 billion in revenue for the current quarter. 14 analysts expect Johnson & Johnson to make $22.36 billion in revenue for the quarter ending Jun 2024. The company’s sales for the same quarters a year ago were $24.75 billion and $25.53 billion respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -13.50%. Forecasts for the next quarter put sales growth at -12.40%.

Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -0.27%. Johnson & Johnson earnings are expected to increase by 7.42% in 2024, but the outlook is positive 4.70% per year for the next five years.

JNJ Dividends

Johnson & Johnson’s next quarterly earnings report is expected to be released on April 16. The annual dividend yield of the stock is 3.02 percent and its annual dividend per share was 4.76. It is important to note, however, that the 3.02% dividend yield ratio should be regarded as a guide only, as many other factors should be taken into consideration before making any investment decision.

Johnson & Johnson (NYSE:JNJ)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 0.09% of Johnson & Johnson shares, and 71.28% of them are in the hands of institutional investors. The stock currently has a share float of 71.34%. Johnson & Johnson stock is held by 4,784 institutions, with Vanguard Group Inc being the largest institutional investor. By Jun 29, 2023, it held 9.52% of the shares, which is about 247.48 million shares worth $40.96 billion.

Blackrock Inc., with 7.67% or 199.34 million shares worth $33.0 billion as of Jun 29, 2023, holds the second largest percentage of outstanding shares.

Vanguard Total Stock Market Index Fund and Vanguard 500 Index Fund were the top two Mutual Funds as of Jun 29, 2023. The former held 81.05 million shares worth $13.42 billion, making up 3.12% of all outstanding shares. On the other hand, Vanguard 500 Index Fund held roughly 61.87 million shares worth around $10.24 billion, which represents about 2.38% of the total shares outstanding.